{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T14:35:55Z","timestamp":1773326155981,"version":"3.50.1"},"reference-count":71,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2015,3,1]],"date-time":"2015-03-01T00:00:00Z","timestamp":1425168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,3,1]],"date-time":"2015-03-01T00:00:00Z","timestamp":1425168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Formosan Medical Association"],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.1016\/j.jfma.2014.09.001","type":"journal-article","created":{"date-parts":[[2014,10,8]],"date-time":"2014-10-08T21:48:42Z","timestamp":1412804922000},"page":"204-215","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Emerging treatments for chronic hepatitis C"],"prefix":"10.1016","volume":"114","author":[{"given":"C. Nelson","family":"Hayes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuaki","family":"Chayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jfma.2014.09.001_bib1","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1002\/hep.26141","article-title":"Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence","volume":"57","author":"Mohd Hanafiah","year":"2013","journal-title":"Hepatology"},{"issue":"Suppl. 1","key":"10.1016\/j.jfma.2014.09.001_bib2","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/j.1478-3231.2008.01934.x","article-title":"The global burden of hepatitis C","volume":"29","author":"Lavanchy","year":"2009","journal-title":"Liver Int"},{"key":"10.1016\/j.jfma.2014.09.001_bib3","doi-asserted-by":"crossref","first-page":"346","DOI":"10.7326\/0003-4819-140-5-200403020-00010","article-title":"Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose","volume":"140","author":"Hadziyannis","year":"2004","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jfma.2014.09.001_bib4","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","article-title":"Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial","volume":"358","author":"Manns","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.jfma.2014.09.001_bib5","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa020047","article-title":"Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection","volume":"347","author":"Fried","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2014.09.001_bib6","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1056\/NEJMoa1012912","article-title":"Telaprevir for previously untreated chronic hepatitis C virus infection","volume":"364","author":"Jacobson","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2014.09.001_bib7","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1056\/NEJMoa1013086","article-title":"Telaprevir for retreatment of HCV infection","volume":"364","author":"Zeuzem","year":"2011","journal-title":"N Engl J Med"},{"issue":"Suppl. 1","key":"10.1016\/j.jfma.2014.09.001_bib8","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/liv.12423","article-title":"HCV direct-acting antiviral agents: the best interferon-free combinations","volume":"34","author":"Schinazi","year":"2014","journal-title":"Liver Int"},{"key":"10.1016\/j.jfma.2014.09.001_bib9","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.jfma.2013.08.013","article-title":"Extensive inflammation of actinic keratoses during interferon alpha therapy for chronic hepatitis C in a Taiwanese albino woman","volume":"112","author":"Yang","year":"2013","journal-title":"J Formos Med Assoc"},{"key":"10.1016\/j.jfma.2014.09.001_bib10","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0168-8278(96)80113-9","article-title":"Side effects of high-dose interferon therapy for chronic hepatitis C","volume":"25","author":"Okanoue","year":"1996","journal-title":"J Hepatol"},{"key":"10.1016\/j.jfma.2014.09.001_bib11","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1128\/AAC.50.3.899-909.2006","article-title":"Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease","volume":"50","author":"Perni","year":"2006","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1016\/j.jfma.2014.09.001_bib12","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1126\/science.1082604","article-title":"Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease","volume":"300","author":"Foy","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.jfma.2014.09.001_bib13","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1053\/j.gastro.2006.07.013","article-title":"Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study","volume":"131","author":"Reesink","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jfma.2014.09.001_bib14","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1053\/j.gastro.2007.02.037","article-title":"Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir","volume":"132","author":"Sarrazin","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jfma.2014.09.001_bib15","doi-asserted-by":"crossref","first-page":"114","DOI":"10.7326\/0003-4819-158-2-201301150-00576","article-title":"Comparative effectiveness of antiviral treatment for hepatitis C virus infection in adults: a systematic review","volume":"158","author":"Chou","year":"2013","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jfma.2014.09.001_bib16","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0140-6736(10)60934-8","article-title":"Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial","volume":"376","author":"Kwo","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jfma.2014.09.001_bib17","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1010494","article-title":"Boceprevir for untreated chronic HCV genotype 1 infection","volume":"364","author":"Poordad","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2014.09.001_bib18","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1009482","article-title":"Boceprevir for previously treated chronic HCV genotype 1 infection","volume":"364","author":"Bacon","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2014.09.001_bib19","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1056\/NEJMoa1014463","article-title":"Response-guided telaprevir combination treatment for hepatitis C virus infection","volume":"365","author":"Sherman","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2014.09.001_bib20","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1002\/hep.25764","article-title":"Response-guided telaprevir therapy in prior relapsers? The role of bridging data from treatment-naive and experienced subjects","volume":"57","author":"Liu","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2014.09.001_bib21","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jhep.2011.07.016","article-title":"Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan","volume":"56","author":"Kumada","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.jfma.2014.09.001_bib22","doi-asserted-by":"crossref","first-page":"e134","DOI":"10.1111\/j.1365-2893.2011.01528.x","article-title":"Efficacy and safety of telaprevir, a new protease inhibitor, for difficult-to-treat patients with genotype 1 chronic hepatitis C","volume":"19","author":"Hayashi","year":"2012","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jfma.2014.09.001_bib23","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1111\/j.1872-034X.2010.00726.x","article-title":"Accumulation of refractory factors for pegylated interferon plus ribavirin therapy in older female patients with chronic hepatitis C","volume":"40","author":"Chayama","year":"2010","journal-title":"Hepatol Res"},{"key":"10.1016\/j.jfma.2014.09.001_bib24","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1093\/cid\/cir774","article-title":"Boceprevir and telaprevir in the management of hepatitis C virus-infected patients","volume":"54","author":"Butt","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jfma.2014.09.001_bib25","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2014.03.051","article-title":"Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis","volume":"147","author":"H\u00e9zode","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jfma.2014.09.001_bib26","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1002\/hep.24460","article-title":"Rapid emergence of telaprevir resistant hepatitis C virus strain from wildtype clone in\u00a0vivo","volume":"54","author":"Hiraga","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2014.09.001_bib27","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1007\/s00535-011-0411-0","article-title":"Antiviral effects of peginterferon alpha-2b and ribavirin following 24-week monotherapy of telaprevir in Japanese hepatitis C patients","volume":"46","author":"Ozeki","year":"2011","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.jfma.2014.09.001_bib28","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jhep.2011.01.011","article-title":"Hepatitis C virus resistance to protease inhibitors","volume":"55","author":"Halfon","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.jfma.2014.09.001_bib29","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1056\/NEJMoa1104430","article-title":"Preliminary study of two antiviral agents for hepatitis C genotype 1","volume":"366","author":"Lok","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2014.09.001_bib30","first-page":"139","article-title":"Beyond telaprevir and boceprevir: resistance and new agents for hepatitis C virus infection","volume":"20","author":"Wyles","year":"2012","journal-title":"Top Antivir Med"},{"key":"10.1016\/j.jfma.2014.09.001_bib31","first-page":"1","article-title":"Chronic hepatitis C: future treatment","volume":"6","author":"Wendt","year":"2014","journal-title":"Clin Pharmacol"},{"key":"10.1016\/j.jfma.2014.09.001_bib32","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1021\/jm401507s","article-title":"Discovery and development of simeprevir (TMC435), a HCV NS3\/4A protease inhibitor","volume":"57","author":"Rosenquist","year":"2014","journal-title":"J Med Chem"},{"key":"10.1016\/j.jfma.2014.09.001_bib33","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0140-6736(14)60494-3","article-title":"Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial","volume":"384","author":"Jacobson","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.jfma.2014.09.001_bib34","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/S0140-6736(14)60538-9","article-title":"Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"384","author":"Manns","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.jfma.2014.09.001_bib35","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1053\/j.gastro.2014.02.051","article-title":"Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial","volume":"146","author":"Forns","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jfma.2014.09.001_bib36","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.jhep.2014.04.004","article-title":"Simeprevir with peginterferon\/ribavirin for treatment-naive hepatitis C genotype 1 patients in Japan: CONCERTO-1, a phase III trial","volume":"61","author":"Hayashi","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.jfma.2014.09.001_bib37","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1007\/s00535-014-0949-8","article-title":"Once-daily simeprevir with peginterferon and ribavirin for treatment-experienced HCV genotype 1-infected patients in Japan: the CONCERTO-2 and CONCERTO-3 studies","volume":"49","author":"Izumi","year":"2014","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.jfma.2014.09.001_bib38","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2013.10.058","article-title":"Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial","volume":"146","author":"Zeuzem","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jfma.2014.09.001_bib39","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1038\/13305","article-title":"Crystal structure of the RNA-dependent RNA polymerase from hepatitis C virus reveals a fully encircled active site","volume":"6","author":"Lesburg","year":"1999","journal-title":"Nat Struct Biol"},{"issue":"Suppl. 1","key":"10.1016\/j.jfma.2014.09.001_bib40","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/liv.12068","article-title":"New therapeutic strategies in HCV: polymerase inhibitors","volume":"33","author":"Gerber","year":"2013","journal-title":"Liver Int"},{"key":"10.1016\/j.jfma.2014.09.001_bib41","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S1473-3099(13)70033-1","article-title":"Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial","volume":"13","author":"Lawitz","year":"2013","journal-title":"Lancet Infect Dis"},{"issue":"Suppl. 2","key":"10.1016\/j.jfma.2014.09.001_bib42","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/S0168-8278(12)00243-7","article-title":"1 ATOMIC: 97% RVR for PIS7977 + REG\/RBV \u00d7 12 week regimen in HCV GT1: end to response-guided therapy?","volume":"56","author":"Kowdlev","year":"2012","journal-title":"J Hepatol."},{"key":"10.1016\/j.jfma.2014.09.001_bib43","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1056\/NEJMoa1214853","article-title":"Sofosbuvir for previously untreated chronic hepatitis C infection","volume":"368","author":"Lawitz","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2014.09.001_bib44","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/nrmicro1645","article-title":"Replication of hepatitis C virus","volume":"5","author":"Moradpour","year":"2007","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.jfma.2014.09.001_bib45","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1007\/s12272-011-0921-6","article-title":"Discovery of hepatitis C virus NS5A inhibitors as a new class of anti-HCV therapy","volume":"34","author":"Lee","year":"2011","journal-title":"Arch Pharm Res"},{"key":"10.1016\/j.jfma.2014.09.001_bib46","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2174\/1874091X00903010039","article-title":"The hepatitis C virus NS5A stimulates NS5B during in\u00a0vitro RNA synthesis in a template specific manner","volume":"3","author":"Quezada","year":"2009","journal-title":"Open Biochem J"},{"key":"10.1016\/j.jfma.2014.09.001_bib47","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.jhep.2013.03.030","article-title":"NS5A inhibitors in the treatment of hepatitis C","volume":"59","author":"Pawlotsky","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.jfma.2014.09.001_bib48","doi-asserted-by":"crossref","first-page":"4765","DOI":"10.1038\/srep04765","article-title":"Potent hepatitis C inhibitors bind directly to NS5A and reduce its affinity for RNA","volume":"4","author":"Ascher","year":"2014","journal-title":"Sci Rep"},{"key":"10.1016\/j.jfma.2014.09.001_bib49","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1002\/hep.24724","article-title":"Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders","volume":"55","author":"Chayama","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2014.09.001_bib50","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.jhep.2013.10.019","article-title":"Randomized trial of daclatasvir and asunaprevir with or without PegIFN\/RBV for hepatitis C virus genotype 1 null responders","volume":"60","author":"Lok","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.jfma.2014.09.001_bib51","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1002\/hep.27113","article-title":"Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection","volume":"59","author":"Kumada","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2014.09.001_bib52","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/S0140-6736(14)61059-X","article-title":"All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study","volume":"384","author":"Manns","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.jfma.2014.09.001_bib53","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1053\/j.gastro.2013.10.057","article-title":"Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection","volume":"146","author":"Everson","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jfma.2014.09.001_bib54","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1306218","article-title":"Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection","volume":"370","author":"Sulkowski","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2014.09.001_bib55","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1056\/NEJMoa1316366","article-title":"Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection","volume":"370","author":"Afdhal","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2014.09.001_bib56","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1056\/NEJMoa1402454","article-title":"Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection","volume":"370","author":"Afdhal","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2014.09.001_bib57","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1056\/NEJMoa1402355","article-title":"Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis","volume":"370","author":"Kowdley","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2014.09.001_bib58","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1056\/NEJMoa1214854","article-title":"Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options","volume":"368","author":"Jacobson","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2014.09.001_bib59","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJMoa1316145","article-title":"Sofosbuvir and ribavirin in HCV genotypes 2 and 3","volume":"370","author":"Zeuzem","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2014.09.001_bib60","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/S0140-6736(14)61036-9","article-title":"Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study","volume":"384","author":"Lawitz","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.jfma.2014.09.001_bib61","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1208809","article-title":"Exploratory study of oral combination antiviral therapy for hepatitis C","volume":"368","author":"Poordad","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2014.09.001_bib62","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1056\/NEJMoa1315722","article-title":"Treatment of HCV with ABT-450\/r-ombitasvir and dasabuvir with ribavirin","volume":"370","author":"Feld","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2014.09.001_bib63","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1056\/NEJMoa1402338","article-title":"ABT-450\/r-ombitasvir and dasabuvir with or without ribavirin for HCV","volume":"370","author":"Ferenci","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2014.09.001_bib64","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1056\/NEJMoa1401561","article-title":"Retreatment of HCV with ABT-450\/r-ombitasvir and dasabuvir with ribavirin","volume":"370","author":"Zeuzem","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2014.09.001_bib65","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa1402869","article-title":"ABT-450\/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis","volume":"370","author":"Poordad","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2014.09.001_bib66","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1056\/NEJMoa1213557","article-title":"Faldaprevir and deleobuvir for HCV genotype 1 infection","volume":"369","author":"Zeuzem","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2014.09.001_bib67","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jhep.2013.02.009","article-title":"A phase 2a trial of 12-week interferon-free therapy with two direct-acting antivirals (ABT-450\/r, ABT-072) and ribavirin in IL28B C\/C patients with chronic hepatitis C genotype 1","volume":"59","author":"Lawitz","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.jfma.2014.09.001_bib68","article-title":"Mericitabine and ritonavir-boosted danoprevir with or without ribavirin in treatment-naive HCV genotype 1 patients: INFORM-SVR study","author":"Gane","year":"2014","journal-title":"Liver Int"},{"key":"10.1016\/j.jfma.2014.09.001_bib69","first-page":"S55","article-title":"Safety and efficacy of the all-oral regimen of MK-5172\/MK-8742\u00b1ribavirin in treatment-naive, non-cirrhotic, patients with hepatitis C virus genotype 1 infection: the C-WORTHy study","volume":"vol. 60","author":"Hezode","year":"2014"},{"key":"10.1016\/j.jfma.2014.09.001_bib70","first-page":"S25","article-title":"Efficacy and safety of MK-5172 and MK-8742\u00b1ribavirin in hepatitis C genotype 1 infected patients with cirrhosis or previous null-response: the C-WORTHy study","volume":"vol. 60","author":"Lawitz","year":"2014"},{"key":"10.1016\/j.jfma.2014.09.001_bib71","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1517\/14656566.2013.795543","article-title":"Hepatitis C therapy with HCV NS5B polymerase inhibitors","volume":"14","author":"Soriano","year":"2013","journal-title":"Expert Opin Pharmacother"}],"container-title":["Journal of the Formosan Medical Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664614002630?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664614002630?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T14:37:48Z","timestamp":1760539068000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0929664614002630"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3]]},"references-count":71,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,3]]}},"alternative-id":["S0929664614002630"],"URL":"https:\/\/doi.org\/10.1016\/j.jfma.2014.09.001","relation":{},"ISSN":["0929-6646"],"issn-type":[{"value":"0929-6646","type":"print"}],"subject":[],"published":{"date-parts":[[2015,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Emerging treatments for chronic hepatitis C","name":"articletitle","label":"Article Title"},{"value":"Journal of the Formosan Medical Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jfma.2014.09.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Published by Elsevier (Singapore) Pte Ltd.","name":"copyright","label":"Copyright"}]}}